Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday. 

Pfizer said the Phase 3 clinical trial began in late July 2020 and completed enrollment of 46,331 participants in January, including over 2,200 participants aged 12-15. The company also plans to study the vaccine in pregnant women, among other populations. 

Vaccines from Pfizer and Moderna Inc. are not currently available for use in children due to a lack of studies. The Food and Drug Administration last month authorized emergency use of the vaccine for individuals age 16 and older. 

Related News Articles

Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…
News
To enjoy a healthy Thanksgiving with family and friends, get vaccinated against the flu and COVID-19. That’s the message of AHA’s latest United Against the Flu…